Skip to main content
Go to the home page of the European Commission (opens in new window)
English English
CORDIS - EU research results
CORDIS
Content archived on 2024-05-18

Development of a new topic formulation of icrf-187 (dexrazoxane) for treatment of psoriasis

Objective

Razoxane 5ICRF-159) has been shown to have clear dose dependent efficacy in treatment of patients with psoriasis refractory to other conventional therapies. In an attempt to improve the therapeutic index of Razoxane, i.e. maintening high efficacy and lowering the dose-limiting neutropenia, its detrox-enantiomereICRF-187 has been developed. It is known that doses up till 1/3 of MTD (maximum treatment dose) do not cause any significant drop in peripheral leukocyte counts. This project has been designed to determine the following:
1. Confirmation of the efficacy and safety of i.v. administered, commercially available ICRF-187 (trademark CARDIOXANE in EU, ZINECARD in USA and CAN)
2. Development of a new drug formulation: cream or ointment for topical treatment of skin lesions.
3. Detailed study of pre-clinical and clinical efficacy of new formulation
4. Development of pharmacological, toxicological and clinical documentation necessary to support registration in EU countries.

Fields of science (EuroSciVoc)

CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.

This project has not yet been classified with EuroSciVoc.
Be the first one to suggest relevant scientific fields and help us improve our classification service

You need to log in or register to use this function

Topic(s)

Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.

Call for proposal

Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.

Data not available

Funding Scheme

Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.

EAW - Exploratory awards

Coordinator

CSC PHARMACEUTICALS HANDELSGES. MBH
EU contribution
No data
Address
Heiligenstaederstrasse 395B
1190 WIEN
Austria

See on map

Total cost

The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.

No data

Participants (1)

My booklet 0 0